Global Alzheimer's Drugs Market: Trends, Share, Size, Growth, Opportunity, and Forecast 2025

 

Alzheimer's is a type of dementia that affects a patient's behavior, thinking, and memory. Neurons connected to the part of the brain associated with learning to deteriorate as the disease advances slowly. More than 60% of dementia cases are of this type, which affects people 65 and older most frequently. Alzheimer's disease is primarily brought on by the buildup of a protein called beta-amyloid in the spaces between nerve cells as a result of genetic mutation.

North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa make up the segments of the global market for Alzheimer's medications. North America is expected to experience growth in the global market for Alzheimer’s Drugs Market during the forecasted period as a result of rising Alzheimer's disease prevalence and the presence of international players.

North America is expected to experience growth in the global market for Alzheimer’s Drugs Market medications during the forecasted period as a result of rising Alzheimer's disease prevalence and the presence of international players. The Alzheimer's Association estimates that 5.8 million Americans currently have Alzheimer's disease, and that number will rise to 14 million by 2050, fueling the demand for Alzheimer's medications in North America. By the end of 2026, it is anticipated that the market in Europe will grow as a result of rising Alzheimer's disease cases and better diagnostic tools. During the forecast period, it is anticipated that growing healthcare infrastructure in the Asia Pacific and Latin America and increased public awareness of Alzheimer's disease will drive the market growth of the Alzheimer’s Drugs Market.

 Key players

Pfizer, Inc., Janssen Pharmaceutical, Novartis International AG, Eisai Co. Ltd., Lundbeck A/S, and Teva Pharmaceuticals Industries Ltd. are important market participants in the Alzheimer's drug space. Eli Lilly and Company, TauRx Pharmaceuticals Ltd., VTV Therapeutics, Hoffman-La Roche Ltd., AstraZeneca plc, and AC Immune are additional well-known companies with products in clinical trials.